

## **DATA SHEET**

## For research use only. Not for use in humans.

Reagent: Raltegravir

Catalog Number: ARP-11680

**Lot Number:** 70047443

Release Category:

**Provided:** Each vial of ARP-11680 contains approximately 2.0 mg of raltegravir (potassium salt).

Description: Raltegravir (Brand name: Isentress®; MK-0518) is an orally bioavailable inhibitor of Human

Immunodeficiency Virus type 1 (HIV-1) integrase. It inhibits the spread of HIV-1 IIIB infection in MT-4 cell culture with 95% cell culture inhibitory concentration values of 19 and 31 nM in medium

containing 10% heat-inactivated fetal bovine serum or 50% normal human serum.

**Special Characteristics:** Formulations containing raltegravir have been used in combination therapy in the treatment of

HIV-1 infection.

CAS Number: 871038-72-1

Chemical Name: N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-

methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidine-

carboxamide, monopotassium salt

Empirical Formula: C<sub>20</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>5</sub>K

Molecular Weight: 482.5

Please refer to the Certificate of Analysis provided by Starks Associates, Inc. (lot NG1-44-1) for

more information.

**Solubility:** Raltegravir is soluble in water and dimethylsulfoxide (DMSO), but only slightly soluble in methanol

and ethanol. It is insoluble in acetonitrile and isopropanol.

**Recommended Storage:** Room temperature

Contributor: NIAID, DAIDS

Citation: Acknowledgment for publications should read "The following reagent was obtained through the

NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: Raltegravir, ARP-11680, contributed

by NIAID, DAIDS."

Biosafety Level: 1 Appropriate safety procedures should always be used with this material. Laboratory safety is

discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see <a href="https://www.cdc.gov/biosafety/publications/bmbl5/index.htm">www.cdc.gov/biosafety/publications/bmbl5/index.htm</a>.

**Disclaimers:** You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at

www.hivreagentprogram.org.

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided

NIH HIV Reagent Program www.hivreagentprogram.org

E-mail: contact@HIVReagentProgram.org

Tel: 888-487-0727 Fax: 703-365-2898



for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:** 

This material is distributed for internal research purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

NOTE:

Not available for release to commercial organizations.

Recipient agrees that the reagent (Raltegravir) use is permitted only as a standard for *in vitro* and/or studies in animals for inhibition of HIV replication.

ATCC® is a trademark of the American Type Culture Collection.

